^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | zenocutuzumab (MCLA-128) (HER2 inhibitor, HER3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Zenocutuzumab: An antibody that can overcome HER3 mediated HRG signalling in tumor cells by docking on HER2
Published date:
03/10/2021
Excerpt:
Zenocutuzumab uses a Dock & Block™ mechanism for potent and specific tumor targeting and simultaneous inhibition of HRG-driven proliferation of HER2-amplified tumors, even at supramaximal concentrations of HRG
